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SPARC gene expression is reduced in early diabetes-related kidney
growth. Renal enlargement is a characteristic feature of diabetes in
humans and experimental animals that may predict subsequent renal
disease. The biological processes involved in diabetes-related kidney
growth are complex and involve changes in extracellular matrix, cell
hypertrophy and hyperplasia. Secreted protein acidic and rich in cysteine
(SPARC) is an extracellular matrix protein with anti-adhesive, antiprolif-
erative and matrix remodeling properties. We examined kidney SPARC
gene expression and protein content in early experimental diabetes. By
Northern blot analysis, kidney SPARC mRNA fell in diabetic animals at
day ito 40 15% of controls levels (mean SEM, P < 0.01), to 42%
11% on day 3 (P < 0.01) with a further decrease at day 7 to 29 7% (P
< 0.001). In situ hybridization demonstrated SPARC mRNA within
glomeruli, renal interstitial cells and in blood vessels but not in tubular
epithelial cells. SPARC inRNA was decreased in diabetic rats without a
change in the pattern of distribution. By immunofluorescence, SPARC
protein was detected in glomeruli and tubular basement membrane.
Diabetes was associated with a decrease in SPARC protein at both sites.
These data demonstrate that the onset of diabetes-related kidney growth
is associated with a reduction in SPARC mRNA and protein. In the
context of the known biological actions of SPARC, the findings in the
present study implicate this matrix protein in the pathogenesis of diabetes
related kidney growth.
Renal enlargement is a characteristic feature of diabetes mel-
litus. Increased renal size and associated glomerular hyperfiltra-
tion may be predictive of subsequent nephropathy in patients with
insulin-dependent diabetes mellitus (IDDM or type I) [1] and
non-insulin-dependent diabetes mellitus (NIDDM or type II) [2].
In experimental animals the induction of diabetes with either
alloxan or streptozotocin, or its spontaneous development in the
BB rat is associated with renal enlargement [3]. In the streptozo-
tocin rat model renal growth begins within 36 hours of the
development of glycosuria and continues such that by three days
kidney size has increased by 15%. Renal growth subsequently
slows but persists for the next few weeks despite a reduction in rat
body weight [4].
The mechanisms involved in diabetes-induced renal growth are
poorly understood but include the elaboration of locally active
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growth factors and extracellular matrix proteins that interact with
each other and with cell surfaces via integrin and growth factor
receptors [5]. Recently, a group of glycoproteins that modulate
cell-matrix interactions has been identified [6]. The prototype of
these anti-adhesive molecules is SPARC (secreted protein acidic
and rich in cysteine), first isolated from periosteum in 1981 [7] and
originally named osteonectin because of its affinity for type I
collagen, hydroxyapatite and calcium [8]. Its subsequent isolation
from a variety of non-mineralized tissues including the En-
gelbreth-Hoim-Swarm basement membrane tumor as BM-40 in
1986 [9] has given rise to a greater understanding of its role in
modulating cell-matrix interactions, matrix remodeling and
growth factor-matrix interactions [10].
The aim of the present study was to examine changes in SPARC
gene expression and protein content in the kidney during the early
phase of diabetes-related kidney growth.
Methods
Animal model
Fifty-six male Sprague-Dawley rats were randomized to control
and diabetic groups. Diabetes was induced in 33 rats by the
intravenous administration of streptozotocin (STZ) 50 mg/kg
body weight. The remaining 23 rats were injected with citrate
buffer and served as controls. Three groups of seven diabetic and
six control rats were sacrificed at one, three and seven days,
respectively. Seven STZ treated rats were rendered euglycemic by
the subcutaneous insertion of 1.5 silastic pellets of insulin as
previously described [11]. A further five control and five STZ-
diabetic animals were sacrificed at day 7 for in situ hybridization
and immunofluorescence studies as outlined below. At sacrifice,
the animal and both kidneys were weighed and diabetes was
confirmed by measurement of plasma glucose by a glucose oxidase
technique [12]. The kidneys were then excised and their capsule
removed.
RNA preparation and Northern blot analysis
For kidneys used in Northern blot analysis the upper pole of
the left kidney was removed and glomeruli were isolated from
the remaining tissue by serial sieving [13]. Specimens thus ob-
tained were > 90% pure glomeruli. Both the glomeruli and left
kidney remnant were snap frozen in liquid nitrogen and stored at
—80°C. Tissues were later homogenized (Ultra-Turrax, Janke and
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Fig. 1. Northern blot of mRNA for SPARC in whole kidney (A) and glomemli (B) in control (C) and diabetic (D) animals.
Kunkel, Staufen, Germany) and total RNA was isolated by the
acid guanidinium thiocyanate-phenol-chioroform extraction
method [14]. RNA purity and concentration were determined
spectrophotometrically. Twenty microgram samples were dena-
tured and electrophoresed through 0.8% agarose formaldehyde
gels. RNA integrity was verified by examination of the 28S and
18S ribosomal bands of ethidium bromide stained material under
ultraviolet light. RNA was then transferred onto nylon filters
(Hybond-N, Amersham, UK) by capillaiy action and fixed by
ultraviolet irradiation.
Filters were hybridized with a 600 bp EcoRI cDNA probe
coding for murine SPARC (gift of Dr. R. Timpl, Max-Planck
Institute, Martinsried, Germany) [15]. The probe was labeled
with [a-32PJ dCTP (DuPont, Boston, MA, USA) by random
primed DNA synthesis. Hybridization was performed at 42°C
for 24 hours in 50% formamide, 45 mrvi Na2HPO4, 5x Denhardt's
solution, 0.5% SDS and sonicated salmon sperm DNA. Filters
were then washed in solutions of decreasing ionic strength
and increasing temperature. The final stringency was 0.1 X
standard saline citrate (SSC) with 0.1% SDS for 20 minutes at
42°C. Filters were then exposed to X-ray film (Kodak X-Omat,
Eastman-Kodak, Rochester, NY, USA) at —80°C for one to five
days. The relative intensity of autoradiograms was determined by
scanning densitometry (LKB Ultroscan XL, Bromma, Sweden).
All results were corrected for differences in RNA loading by
rehybridization with an oligonucleotide probe for 18S rRNA end
labeled with [ts-32Pj dCTP by terminal transferase (Boehringer
Mannheim, Mannheim, Germany).
 
1218 Gilbert et a!: Renal SPARC mRNA in diabetes
Tissue preparation for in situ hybridization
The left kidney of five diabetic and five control animals was
used for in situ hybridization studies. Two millimeter thick kidney
sections were fixed overnight at room temperature in 10% neutral
buffered formalin and then embedded in paraffin. Four microme-
ter thick sections were cut onto slides precoated with 3-aminopro-
pyltriethoxysilane and baked overnight at 37°C.
Riboprobe preparation
The cDNA coding for murine SPARC was cloned in pGEM 4Z
(Promega, Maddison, WI, USA), linearized with Hindlil and a
complementary riboprobe was prepared. Five hundred nano-
grams of linearized template was added to a reaction mixture of
transcription buffer (final volume 20 sl) containing 6 mrvt dithio-
threitol, 333 jM ATP, CTP, GTP, 12 pM UTP, 100 j.tCi [33P] UTP,
20 units RNAsin (Boehringer-Mannheim) and 20 units SP6 RNA
polymerase (Boehringer-Mannheim). The reaction mixture was
incubated at 37°C for 90 minutes following which the DNA
template was digested with 1 p RNAse-free DNAse for 15
minutes. The riboprobe was precipitated by ammonium acetate
and ethanol using yeast tRNA as a carrier and then reconstituted
in 100 gI of DEPC treated water. Purified riboprobe length was
adjusted to approximately 150 bases by alkaline hydrolysis [161.
In situ hybridization
In situ hybridization was performed essentially as previously
described [171. In brief, tissue sections were dewaxed and rehy-
drated in graded ethanol and milliQ water, equilibrated in P
buffer (50 mrvi Tris-HC1, pH 7.5, 5 mvt EDTA) and incubated in
125 g/ml Pronase E in P buffer for 10 minutes at 37°C. Sections
were then washed in 0.1 M sodium phosphate buffer, pH 7.2,
rinsed in milliQ water, dehydrated in 70% ethanol and air dried.
Hybridization buffer containing 2 X i0 cpm/.tl riboprobe in
300 mM NaCl, 10 mi Tris-HC1, pH 7.5, 10 mM Na2HPO4, 5 mM
EDTA, pH 8.0, 1 X Denhardt's solution, 50% formamide, 17
mg/mi yeast RNA, 10% wt/vol dextran sulfate, was heated to 85°C
for five minutes. Twenty-five microliters of this solution were then
added to each section which was then added to each section.
Hybridization was performed overnight at 60°C in 50% form-
amide humidified chambers. As controls for non-specific signal,
sections were incubated with sense riboprobe for SPARC or
treated with RNAse prior to hybridization.
Slides were washed in 2 x SSC containing 50% formamide
prewarmed to 50°C to remove coverslips. Sections were then
washed in the above solution for one hour at 55°C, rinsed three
more times in RNAse buffer (10 mM Tris-HCI, pH 7.5, 1 mrvi
EDTA, pH 8.0, 0.5 M NaCl) and then incubated with RNAse A
(150 jig/mi) for one hour at 37°C. Sections were later washed in 2
x SSC for 45 minutes at 55°C, dehydrated in graded ethanol, air
dried and exposed to Kodak X-Omat autoradiographie film for
three days. Slides were then dipped in Ilford KS nuclear emulsion
(Ilford, Mobberley, Cheshire, UK), stored in a light-free box with
desiccant at 4°C for 21 days, immersed in Kodak D19 developer,
fixed in Ilford Hypan and stained with hematoxylin and eosin.
Immunofluorescence
The right kidney of five diabetic and five control animals was
used for immunofluorescence studies. After removal and decap-
sulation, kidneys were embedded in OCT (Tissue-Tek, Miles,
Elkhart, IN, USA) and rapidly frozen on isopentane precooled
with liquid nitrogen. Cryostat sections (6 jim) were then mounted
on 1% gelatin coated slides, air dried and stored overnight at 4°C
in a vacuum dessicator. Sections were incubated with a polyclonal
rabbit anti-mouse SPARC antibody (#937+, gift of Dr. R. Timpl)
at room temperature for 30 minutes, washed with PBS and
incubated with fluorescein isothiocyanate conjugated anti-rabbit
IgG (Silenus, Laboratories, Hawthorn, Australia) at 37°C for 30
minutes. Sections were then washed with PBS, rinsed in distilled
water and mounted in a fluorescence quenching retardant (Flu-
orSave, Calbiochem, La Jolla, CA, USA). Control sections were
incubated with normal rabbit serum or secondary antiserum alone
to exclude non-specific fluorescence.
Sections were examined by indirect immunofluorescence using
a Zeiss epifluorescence microscope with appropriate filters (Carl
Zeiss, Oberkochen, Germany) and photographic attachment
(Zeiss Axiophot). Sections were graded by two methods. Firstly,
sections were examined by two independent observers blinded to
the disease status of the animal and graded on a scale of 0 to 3+
where 0 = absent, + weak, 2+ moderate and 3+ indicated
strong fluorescence. Using the automatic exposure facility of the
attached camera, immunofluoreseence was also assessed quanti-
tatively by recording the duration of film exposure on multiple
tissue sections from each control and diabetic rat kidney (N =
3/kidney).
Statistics
Results are expressed as mean SEM unless stated otherwise.
Data were analyzed using parametric methods including two-
tailed Student's t-tests for unpaired data and linear regression
analysis. Semiquantitative data derived from scoring immunoflu-
orescence were analyzed by the Mann-Whitney U-test. All anal-
yses were performed using the Statview SE+ Graphics package
(Abacus Concepts, Berkeley, CA, USA) on an Apple Macintosh
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Fig. 3. In situ hybridization of SPARC mRNA in
saggital section of kidney from control (A) and
diabetic (B) rats.
Quadra 605 (Apple Computer mc, Cupertino, CA, USA). A P
value < 0.05 was considered statistically significant.
Results
Animal model
By day 1 all STZ treated animals were diabetic with mean
plasma glucose of 24.4 1.3 mmol/liter (mean SEM) compared
with 7.8 0.2 mmol/liter in controls and 8.0 0.2 mmol/liter in
insulin treated diabetic rats. Similar levels of glycemia persisted
throughout the study period with no diabetic animals reverting to
a non-diabetic state. Despite a weight loss of 8.3% at day 7, the
kidneys of diabetic animals were 11.4% larger than those of
control animals at sacrifice.
Northern blot analysis
In the whole kidney preparation SPARC mRNA fell in diabetic
animals at day 1 to 40 15% that of controls (P < 0.01), to 42%
11% on day 3 (P < 0.01) with a further decrease at day 7 to 29
7% (P < 0.001) (Figs. 1A, and 2A). In contrast, diabetic rats
rendered euglycemic with insulin pellets had similar levels of
SPARC mRNA to controls. Among the diabetic rats whole kidney
SPARC mRNA at day 7 was inversely correlated with kidney
weight (r = —0.75, N = 7, P < 0.05). In glomeruli there was no
significant difference in glomerular SPARC gene expression be-
tween diabetic and control animals on day 1. On day 3, SPARC
mRNA fell in diabetic animals to 57 9% (mean SEM, P <
0.01) of controls levels and returned to that found in control
animals by day 7 (Figs. lB and 2B).
In situ hybridization
In situ hybridization revealed punctate SPARC gene expression
in the outer cortex and in a more diffuse pattern within the
medulla (Fig. 3A). The intensity of labeling appeared less in
kidneys from diabetic animals although the pattern of distribution
was essentially unchanged (Fig. 3B). Emulsion-dipped, hematox-
ylin and eosin counterstained sections demonstrated SPARC
mRNA throughout the glomerulus with hybridization to mesang-
ial, epithelial and endothelial cells (Fig. 4). Gene expression for
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Fig. 3. Continued.
SPARC was also detected in renal vessels and interstitial cells but
not within tubular epithelial cells. Hybridization occurred to all
cell types in the glomerulus. Examination of diabetic rat kidneys
revealed a similar pattern of localization. No hybridization was
observed in sections incubated with RNAse or sense riboprobe.
Immunofluorescence
Immunofluorescence for SPARC was demonstrated in the
tubular basement membrane and diffusely within the glomerular
tuft (Fig. 5). While the distribution of fluorescence was similar, its
intensity was reduced in the kidneys of diabetic rats. By semiquan-
titative scoring less immunofluorescence was observed in tissue
sections from diabetic animals compared with control rats (1.7
0.2 vs. 3.0 0.1, P < 0.01) and similar results were obtained by
recording the duration of film exposure (31.5 3.0 vs. 20.1 1.0
seconds, P < 0.001).
Discussion
The present study has demonstrated a diminution in renal
SPARC gene expression, proportional to kidney weight in asso-
ciation with diabetes-related kidney growth. Furthermore, this
altered gene expression was translated into a reduction in SPARC
protein content in the kidney.
The location of SPARC mRNA and protein within the kidney
has not been extensively investigated. In situ hybridization and
immunofluorescence were therefore undertaken to determine the
sites of SPARC gene expression and protein deposition. In situ
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Fig. 5. Immunofluorescence for SPARC in glomendi (A and B, magnification 500X) and tubulointerstitium (C and D, magnification 300X) from control
(A and C) and diabetic (B and D) rats.
Fig. 4. Darkfield photomicrograph of SPARC mRNA (A) and the same section stained with hematoxylin and eosin (B) showing SPARC transcript
localization to a glomerulus (anow). Magnification 500X.
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Fig. 5. Continued.
1224 Gilbert et al: Renal SPARC mRNA in diabetes
hybridization revealed abundant SPARC mRNA within glomer-
uli, and its translation to SPARC protein at this site was demon-
strated by immunofluorescence. In contrast, renal tubular epithe-
hal cells did not exhibit significant SPARC mRNA, yet displayed
substantial SPARC protein in the tubular basement membrane,
raising the possibility that SPARC generated by renal interstitial
cells (which demonstrated abundant SPARC mRNA) may bind to
other matrix proteins in the tubular basement membrane (such as
type IV collagen) as described [18].
While SPARC has not been previously examined in diabetes,
studies of SPARC in models of non-diabetic kidney disease have
revealed increased SPARC in complement-mediated glomerular
injury [19] where its augmented production is believed to mediate
recovery from injury [20]. Thus, the reduction in SPARC found in
the present study may play a role in the initiation of renal
pathology.
A major component of diabetes-related kidney growth is cell
proliferation. Both in vivo and in vitro studies suggest that SPARC
is antiproliferative, inhibiting cell cycle progression from the G1 to
the S phase [21]. Therefore, the diminution in SPARC found in
the present study is consistent with the transient cell proliferation
described following the induction of experimental diabetes. Fur-
thermore, the reduction in gene expression for SPARC was more
prominent in the whole kidney than glomeruli, consistent with the
greater cell proliferation that occurs in tubular cells compared
with those of the glomerulus in early experimental diabetes [22].
The role of growth factors in the renal enlargement that
accompanies diabetes is not well understood. Early diabetes
related kidney growth has been associated with increased mRNA
for a number of growth factors including transforming growth
factor-a (TGF-13) [23] platelet-derived growth factor (PDGF) [24]
insulin-like growth factor I (IGF-I) [25] and basic fibroblast
growth factor (bFGF) [24]. PDGF is a potent mitogen of many
cell lines and, like SPARC, is found in the kidney [26] and the a
granules of platelets [27]. The ability of SPARC to inhibit PDGF
binding to its receptor [28] suggests that SPARC may have a role
in limiting PDGF activity analogous to the inhibitory effect of
decorin on TGF-3 activity and the action of IGF-I binding
proteins in quenching IGF-I biological activity [29]. Furthermore,
SPARC may antagonize bFGF actions through receptor indepen-
dent mechanisms [30] and possibly reduce TGF-!3 bioactivity as a
function of its follistatin-like domain [10]. Hence, the reduction in
SPARC that follows the development of diabetes may be associ-
ated with increased activity of PDGF, bFGF and possibly TGF-13
thereby exacerbating the effects of the increased gene expression
of these growth factors and further enhancing cell proliferation
and extracellular matrix deposition in the kidney.
Tissue growth is accompanied by increased basement mem-
brane material. The addition of SPARC to cultured cells is
associated with increased expression of several extracellular ma-
trix degrading matrix metalloproteinases (MMP) [31] in addition
to decreased expression of the major matrix glycoprotein fi-
bronectin [32]. Therefore reduced levels of SPARC may lead to
increased matrix protein synthesis and reduced matrix degrada-
tion and thereby contribute to the increase in basement mem-
brane material that accompanies kidney growth in diabetes [33].
Indeed, recent studies have confirmed reduced renal MMP activ-
ity [34] and increased fibronectin [35] in association with kidney
growth following the induction of STZ-diabetes in rats.
Several observations suggest a role for SPARC in cell-matrix
interaction and tissue remodeling. Its constitutive expression in
the kidney suggest that it may have a tonic influence on these
processes in the adult. In vitro, exogenous SPARC produces cell
rounding and prevents cell spreading possibly by interfering with
cell attachment to the underlying matrix in an integrin-indepen-
dent manner [36]. Reduced levels of SPARC in early diabetes may
thus be associated with increased cell spreading and cell length-
ening which may render cells more sensitive to the action of
various growth factors [37].
In summary, experimental diabetes-related kidney growth is
associated with a rapid reduction in renal SPARC mRNA and
protein content, consistent with a role for SPARC in the patho-
genesis of renal growth in diabetes.
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